Neurogene (NGNE) FCF Margin (2018 - 2024)

Neurogene's (NGNE) quarterly FCF Margin came in at 1759.68% in Q2 2024, down 269293.09% on a QoQ basis from 0.65% in Q3 2019.

Analysis

Neurogene (NGNE) FCF Margin (2018 - 2024) Analysis & Trends

Neurogene (NGNE) has 3 years of FCF Margin data on file, last reported at 1759.68% in Q2 2024.

Quarterly FCF Margin changed N/A year-over-year to 1759.68% in Q2 2024, while the trailing twelve-month figure through Jun 2025 was 8042.05% (down 82043.0% YoY) and the FY2024 annual result came in at 7711.24%, changed N/A from the prior year.
FCF Margin slipped to 1759.68% in Q2 2024, from 0.65% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 1759.68% in Q2 2024 to a low of 1759.68% in Q2 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	13.35%
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-388.28%
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	25.68%
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	22.62%
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	70.82%
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-22.35%
10	Neurogene	864.53 Mn	864.53 Mn	-	-

Historic Data

Download Data